Halyard Health Inc (HYH) Sees Unusually-High Trading Volume

Halyard Health Inc (NYSE:HYH) saw unusually-high trading volume on Wednesday , Analyst Ratings Net reports. Approximately 323,236 shares changed hands during trading, a decline of 2% from the previous session’s volume of 329,261 shares.The stock last traded at $33.41 and had previously closed at $32.91.

HYH has been the topic of a number of research reports. Morgan Stanley downgraded shares of Halyard Health from an “equal weight” rating to an “underweight” rating and set a $27.00 price objective on the stock. in a research report on Monday, October 12th. Zacks Investment Research lowered shares of Halyard Health from a “buy” rating to a “strong sell” rating in a research note on Wednesday, October 14th. JMP Securities reiterated a “buy” rating on shares of Halyard Health in a research note on Wednesday, August 5th. Deutsche Bank initiated coverage on shares of Halyard Health in a report on Friday, September 11th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Stifel Nicolaus started coverage on shares of Halyard Health in a report on Wednesday. They set a “buy” rating and a $38.00 price objective on the stock. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $36.25.

The company’s market cap is $1.57 billion. The stock’s 50-day moving average is $30.42 and its 200-day moving average is $34.99.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.05. The firm earned $390 million during the quarter, compared to analyst estimates of $388 million. Halyard Health’s quarterly revenue was down 4.5% on a year-over-year basis. On average, analysts predict that Halyard Health Inc will post $2.06 EPS for the current year.

In related news, CEO Robert E. Abernathy bought 10,000 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $31.06 per share, for a total transaction of $310,600.00. Following the transaction, the chief executive officer now owns 80,043 shares of the company’s stock, valued at $2,486,135.58. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Halyard Health, Inc. seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company has two business segments: Surgical and Infection Prevention (NYSE:HYH) and Medical Devices. The Company’s S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections. S&IP’s product portfolio includes sterilization wrap, surgical drapes and gowns, facial protection, protective apparel and medical exam gloves. Medical Devices segment provides a portfolio of product offerings, including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes, focused on pain management and respiratory and digestive health.

This story was originally published by Putnam Standard (http://putnamstandard.com) and is the sole property of Putnam Standard. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://putnamstandard.com/2015/12/03/halyard-health-inc-hyh-sees-unusually-high-trading-volume/674390/

Halyard Health Inc (HYH) Sees Unusually-High Trading Volume

Shares of Boston Scientific Corporation (NYSE:BSX) Sees Large Outflow of Money

Boston Scientific Corporation (NYSE:BSX) surged 0.06% during the last session. The last traded price was up 0.01 points at $17.96. The data for the fund flow suggests that the net intraday money flow was $(-6.22) million. The fund value in upticks was recorded to be $7.84 million and in downticks, it was found to be $14.06 million. The up/down ratio for the day was measured to be 0.56. For the week, the shares have seen a percentage change of 2.05%.A block trade of $(-5.46) million in net money flow was also recorded during the day. For the block, the combined worth of upticks was $1.16 million and that of downticks was $6.62 million. The block tradeoff had the up/down ratio of 0.18.

Boston Scientific Corporation has dropped 2.5% during the last 3-month period . Year-to-Date the stock performance stands at 35.4%. Shares of Boston Scientific Corporation (NYSE:BSX) rose by 1.93% in the past week and 0.56% for the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 0.47%. Boston Scientific Corporation (NYSE:BSX) has underperformed the index by 0.23% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

Boston Scientific Corporation (NYSE:BSX) witnessed a decline in the market cap on Friday as its shares dropped 0.06% or 0.01 points. After the session commenced at $17.92, the stock reached the higher end at $17.99 while it hit a low of $17.81. With the volume soaring to 5,927,482 shares, the last trade was called at $17.94. The company has a 52-week high of $18.62. The company has a market cap of $24,052 million and there are 1,340,676,000 shares in outstanding. The 52-week low of the share price is $11.1.

On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, The Officer (SVP&Pres, Uro & Womens Health), of Boston Scientific Corp, Prange Karen had unloaded 17,456 shares at $17.66 per share in a transaction on July 7, 2015. The total value of transaction was $308,273. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Womens Health, Neuromodulation, and Electrophysiology. In November 2013, the Company announced that it has acquired Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. In February 2014, Boston Scientific Corp acquired StarMedTec GmbH, a Starnberg-based manufacturer of medical laser systems. Effective May 7, 2014, the Company acquired the remaining 72% interest, which it did not already own, in IoGyn Inc.

Shares of Boston Scientific Corporation (NYSE:BSX) Sees Large Outflow of Money